ContractExclusive Licensing Agreement • April 30th, 2019Contract TypeExclusive Licensing AgreementFiledApril 30th, 2019Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan
Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan